155 related articles for article (PubMed ID: 15754530)
21. Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance.
Sharp SY; Rogers PM; Kelland LR
Clin Cancer Res; 1995 Sep; 1(9):981-9. PubMed ID: 9816070
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function.
Massari C; Brienza S; Rotarski M; Gastiaburu J; Misset JL; Cupissol D; Alafaci E; Dutertre-Catella H; Bastian G
Cancer Chemother Pharmacol; 2000; 45(2):157-64. PubMed ID: 10663631
[TBL] [Abstract][Full Text] [Related]
23. Treatment schedule-dependent effect of 5-fluorouracil and platinum derivatives in colorectal cancer cells.
Takara K; Fujita M; Minegaki T; Yamamoto K; Takahashi M; Yokoyama T; Okumura K
Eur J Pharm Sci; 2012 Feb; 45(3):272-81. PubMed ID: 22155546
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics and toxicodynamics of oxaliplatin in rats: application of a toxicity factor to explain differences in the nephrotoxicity and myelosuppression induced by oxaliplatin and the other platinum antitumor derivatives.
Hanada K; Suda M; Kanai N; Ogata H
Pharm Res; 2010 Sep; 27(9):1893-9. PubMed ID: 20552253
[TBL] [Abstract][Full Text] [Related]
25. Organic cation transporters are determinants of oxaliplatin cytotoxicity.
Zhang S; Lovejoy KS; Shima JE; Lagpacan LL; Shu Y; Lapuk A; Chen Y; Komori T; Gray JW; Chen X; Lippard SJ; Giacomini KM
Cancer Res; 2006 Sep; 66(17):8847-57. PubMed ID: 16951202
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients.
Liu J; Kraut E; Bender J; Brooks R; Balcerzak S; Grever M; Stanley H; D'Ambrosio S; Gibson-D'Ambrosio R; Chan KK
Cancer Chemother Pharmacol; 2002 May; 49(5):367-74. PubMed ID: 11976830
[TBL] [Abstract][Full Text] [Related]
27. The emerging role of oxaliplatin in the treatment of gastric cancer.
Zaniboni A; Meriggi F
J Chemother; 2005 Dec; 17(6):656-62. PubMed ID: 16433197
[TBL] [Abstract][Full Text] [Related]
28. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
Schmidt W; Chaney SG
Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
[TBL] [Abstract][Full Text] [Related]
29. New platinum agents. A comparison in ovarian cancer.
Kelland LR; McKeage MJ
Drugs Aging; 1994 Aug; 5(2):85-95. PubMed ID: 7981487
[TBL] [Abstract][Full Text] [Related]
30. Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin.
Meerum Terwogt JM; Groenewegen G; Pluim D; Maliepaard M; Tibben MM; Huisman A; ten Bokkel Huinink WW; Schot M; Welbank H; Voest EE; Beijnen JH; Schellens JM
Cancer Chemother Pharmacol; 2002 Mar; 49(3):201-10. PubMed ID: 11935212
[TBL] [Abstract][Full Text] [Related]
31. The developmental neurotoxicity study of platinum compounds. Effects of cisplatin versus a novel Pt(II) complex on rat cerebellum.
Cerri S; Piccolini VM; Santin G; Bottone MG; De Pascali SA; Migoni D; Iadarola P; Fanizzi FP; Bernocchi G
Neurotoxicol Teratol; 2011; 33(2):273-81. PubMed ID: 20883777
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic and pharmacological studies of tetrachloro(d,l-trans)1,2-diaminocyclohexane platinum (IV) (tetraplatin), a new platinum analogue.
Rahman A; Roh JK; Wolpert-DeFilippes MK; Goldin A; Venditti JM; Woolley PV
Cancer Res; 1988 Apr; 48(7):1745-52. PubMed ID: 3162402
[TBL] [Abstract][Full Text] [Related]
33. Phase I clinical trial and pharmacokinetics of 4'-carboxyphthalato(1,2-diaminocyclohexane)platinum(II).
Kelsen DP; Scher H; Alcock N; Leyland-Jones B; Donner A; Williams L; Greene G; Burchenal JH; Tan C; Philips FS; Young CW
Cancer Res; 1982 Nov; 42(11):4831-5. PubMed ID: 7127319
[TBL] [Abstract][Full Text] [Related]
34. [Pharmacological approach to the platinum compounds].
Sasaki Y
Gan To Kagaku Ryoho; 1992 Apr; 19(4):456-62. PubMed ID: 1313667
[TBL] [Abstract][Full Text] [Related]
35. Current and future potential roles of the platinum drugs in the treatment of ovarian cancer.
Piccart MJ; Lamb H; Vermorken JB
Ann Oncol; 2001 Sep; 12(9):1195-203. PubMed ID: 11697824
[TBL] [Abstract][Full Text] [Related]
36. Different accumulation of cisplatin, oxaliplatin and JM216 in sensitive and cisplatin-resistant human cervical tumour cells.
Martelli L; Di Mario F; Ragazzi E; Apostoli P; Leone R; Perego P; Fumagalli G
Biochem Pharmacol; 2006 Sep; 72(6):693-700. PubMed ID: 16844093
[TBL] [Abstract][Full Text] [Related]
37. [Development of carboplatin].
Tsukagoshi S
Gan To Kagaku Ryoho; 1990 Sep; 17(9):1949-58. PubMed ID: 2203318
[TBL] [Abstract][Full Text] [Related]
38. Neurotoxicity Associated with Platinum-Based Anti-Cancer Agents: What are the Implications of Copper Transporters?
Stojanovska V; McQuade R; Rybalka E; Nurgali K
Curr Med Chem; 2017; 24(15):1520-1536. PubMed ID: 28079002
[TBL] [Abstract][Full Text] [Related]
39. Current status and future prospects for satraplatin, an oral platinum analogue.
Choy H; Park C; Yao M
Clin Cancer Res; 2008 Mar; 14(6):1633-8. PubMed ID: 18347164
[TBL] [Abstract][Full Text] [Related]
40. Platinum complexes in cancer medicine: pharmacokinetics and pharmacodynamics in relation to toxicity and therapeutic activity.
Calvert H; Judson I; van der Vijgh WJ
Cancer Surv; 1993; 17():189-217. PubMed ID: 8137341
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
